Why Novartis Just Spent $12B on a Tiny Biotech

Novartis completes $12B Avidity acquisition, gaining RNA muscle-targeting platform and three rare neuromuscular therapies

10 Mar 2026

Novartis has finalized its $12 billion acquisition of Avidity Biosciences, securing a promising RNA drug platform and three late stage therapies aimed at rare neuromuscular diseases. The deal closed on February 27, 2026 and ranks among the largest rare disease transactions in pharmaceutical history. It also signals how aggressively big drugmakers are investing in precision medicine.

The centerpiece of the acquisition is Avidity’s antibody oligonucleotide conjugate technology. The platform is designed to deliver RNA medicines directly into muscle tissue, something earlier RNA drugs have struggled to do. Most existing RNA therapies primarily target the liver, leaving many muscle based genetic disorders without viable treatment options.

For patients with rare muscle diseases, the technology offers new hope. By delivering genetic medicines to the right tissue, researchers aim to address the underlying biological drivers of disease rather than simply manage symptoms.

Through the acquisition, Novartis gains three advanced programs targeting Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy. Each condition is progressive and currently lacks approved disease modifying treatments. Novartis plans to submit its Duchenne therapy for regulatory review in 2026, potentially setting up the company for first of their kind product launches before the end of the decade.

The transaction also reshapes Avidity’s remaining pipeline. Early stage precision cardiology programs were spun out into a new company called Atrium Therapeutics, launched the same day with about $270 million in backing. The new firm will focus on rare cardiac diseases while Novartis concentrates on scaling the neuromuscular platform.

Across the industry, the move reflects a larger shift. RNA medicines are moving from experimental science into real commercial pipelines, and companies are racing to secure technologies that can reach tissues beyond the liver. For patients who have long waited for meaningful treatments, that race could finally bring progress within reach.